Edwards Lifesciences reported strong financial results for the first quarter ended March 31, 2025, with total company sales reaching $1.41 billion, representing a 6.2% GAAP growth and 8% constant currency growth. This performance was driven by robust demand across its structural heart portfolio.
Transcatheter Mitral and Tricuspid Therapies (TMTT) sales were a highlight, growing 58% year-over-year to $115 million, or over 60% on a constant currency basis, led by increased adoption of PASCAL and EVOQUE. Transcatheter Aortic Valve Replacement (TAVR) sales grew 3.8% (5.4% constant currency, 6.5% adjusted for billing days) to $1.05 billion, with strong performance from the SAPIEN 3 Ultra RESILIA platform.
The company raised its 2025 TMTT sales guidance range to $530 million to $550 million, up from $500 million to $530 million, due to favorable foreign exchange and business momentum. Edwards also increased its total company sales dollar guidance range by $100 million to $5.7 billion to $6.1 billion, while maintaining its full-year operating margin guidance of 27% to 28% and adjusted EPS guidance of $2.40 to $2.50.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.